At a glance
- Pramlintide was approved by the FDA (Symlin, March 16, 2005), but the products are no longer marketed.
- PubMed lists 451 publications mentioning it, including 64 randomized controlled trials and 28 animal-only studies.
- ClinicalTrials.gov lists 64 registered studies testing it (5 active).
- FDA's adverse event system (FAERS) holds 3,069 reports mentioning it; 628 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA021332 | SYMLIN | Approved, discontinued | March 16, 2005 | ASTRAZENECA AB |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Plasma amylin levels in migraine and after erenumab treatment: A REFORM study.
- Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.
- Metal-tuned antimicrobial peptides and zincophore pathways: from coordination chemistry to targeted therapeutics.
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
- The story of amylin: from physiology to therapy.
- In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.
- Systemic Pharmacokinetic Principles of Therapeutic Peptides.
- Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 64
- Active
- 5
- With posted results
- 15
Conditions studied
Show 40 more studies
All 64 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 3,069
- Serious
- 628
- With death outcome
- 40
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Original FDA text (English) WARNING: SEVERE HYPOGLYCEMIA SYMLIN use with insulin increases the risk of severe hypoglycemia, particularly in patients with type 1 diabetes. When severe hypoglycemia occurs, it is seen within 3 hours following a SYMLIN injection. Serious injuries may occur if severe hypoglycemia occurs while operating a motor vehicle, heavy machinery, or while engaging in other high-risk activities. Appropriate patient selection, careful patient instruction, and insulin dose reduction are critical elements for reducing this risk. WARNING: SEVERE HYPOGLYCEMIA See full prescribing information for complete boxed warning. • SYMLIN use with insulin has been associated with an increased risk of severe hypoglycemia, particularly in patients with type 1 diabetes. • Hypoglycemia risk may be reduced by appropriate patient selection, careful patient instruction, and insulin dose reduction (5.1 , 5.2) . Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.